Evidence map›Paper›PMID 22418868›Full record

ArticleThe Journal of investigative dermatology2012

Urea uptake enhances barrier function and antimicrobial defense in humans by regulating epidermal gene expression.

Susanne Grether-Beck, Ingo Felsner, Heidi Brenden, Zippora Kohne, Marc Majora, Alessandra Marini, Thomas Jaenicke, Marina Rodriguez-Martin, Carles Trullas, Melanie Hupe and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of investigative dermatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
21.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it, 173 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Targeting Skin Barrier Function in Atopic Dermatitis.The journal of allergy and clinical immunology. In practice · 2023
    Article
  12. The foot in diabetes - a reminder of an ever-present risk.Clinical medicine (London, England) · 2023
    Review
  13. Aquaporins in Skin.Advances in experimental medicine and biology · 2023
    Article
  14. Article
  15. Article
  16. Transport Characteristics of Aquaporins.Advances in experimental medicine and biology · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. Beyond CaPflugers Archiv : European journal of physiology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Susanne Grether-BeckInstitut fuer Umweltmedizinische Forschung, Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany. Grether-Beck@uni-duesseldorf.de
Ingo Felsner
Heidi Brenden
Zippora Kohne
Marc Majora
Alessandra Marini
Thomas Jaenicke
Marina Rodriguez-Martin
Carles Trullas
Melanie Hupe
Peter M Elias
Jean Krutmann
Leibniz Institute of Environmental Medicine · DESan Francisco VA Medical Center · USHospital Universitario de Canarias · ESIsdin (Spain) · ES

Funding

NATURE OF THE MAMMALIAN CUTANEOUS PERMEABILITY BARRIERR01AR019098 · NIAMS · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI ELIAS, PETER M · 1986 to 2012
$4.2M
NIAMS NIH HHS AR19098NIAMS NIH HHS R01 AR019098
6 · The paper itself

Abstract

Urea is an endogenous metabolite, known to enhance stratum corneum hydration. Yet, topical urea anecdotally also improves permeability barrier function, and it appears to exhibit antimicrobial activity. Hence, we hypothesized that urea is not merely a passive metabolite, but a small-molecule regulator of epidermal structure and function. In 21 human volunteers, topical urea improved barrier function in parallel with enhanced antimicrobial peptide (AMP; LL-37 and β-defensin-2) expression. Urea stimulates the expression of, and is transported into, keratinocytes by two urea transporters (UTs), UT-A1 and UT-A2, and by aquaporins 3, 7, and 9. Inhibitors of these UTs block the downstream biological effects of urea, which include increased mRNA and protein levels of (i) transglutaminase-1, involucrin, loricrin, and filaggrin, (ii) epidermal lipid synthetic enzymes, and (iii) cathelicidin/LL-37 and β-defensin-2. Finally, we explored the potential clinical utility of urea, showing that topical urea applications normalized both barrier function and AMP expression in a murine model of atopic dermatitis. Together, these results show that urea is a small-molecule regulator of epidermal permeability barrier function and AMP expression after transporter uptake, followed by gene regulatory activity in normal epidermis, with potential therapeutic applications in diseased skin.

Indexed as

AdultAnimalsAntimicrobial Cationic PeptidesAquaporin 3AquaporinsCell DifferentiationCell Membrane PermeabilityDermatitis, AtopicEpidermal CellsEpidermisFemaleFilaggrin ProteinsGene Expression RegulationHumansKeratinocytesMaleAntimicrobial Cationic PeptidesAQP3 protein, humanAQP7 protein, humanAQP9 protein, humanAquaporin 3AquaporinsFilaggrin ProteinsFLG protein, humanMembrane Transport ProteinsUreaUrea TransportersWater

Identifiers

PMID22418868
PMCPMC3352965
OpenAlexW2147701916

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.